GLP-1 Body Contouring Program
GLP-1 agonist + aesthetic medicine combined body program
About This Treatment
The GLP-1 Body Contouring Program combines medical weight loss via GLP-1 receptor agonists (semaglutide/tirzepatide) with strategic aesthetic treatments.
GLP-1 agonists achieve 15-22% weight loss, but rapid reduction causes "Ozempic face" (facial volume loss) and skin laxity. This program strategically combines fillers, skin tightening, biostimulators, and body contouring with weight loss phases for optimal aesthetic outcomes.
Mechanism of Action
GLP-1 agonists stimulate pancreatic β-cell insulin secretion, delay gastric emptying, and suppress hypothalamic appetite centers for 15-22% weight loss. Aesthetic treatments staged by phase: ①Early: skin boosters + biostimulators; ②Mid: RF tightening + EMS; ③Late: fillers + threads for volume restoration.
Indications
Expected Results
Average 15-22% weight loss with GLP-1 agonists. Strategic aesthetic combination minimizes facial volume loss while managing weight. ASPS 2025: body contouring fastest-growing segment among 1.6M cosmetic procedures.
Clinical Evidence
Risks & Side Effects
GLP-1 side effects: nausea/vomiting/diarrhea (early), gallstones, rare pancreatitis. Risk of muscle/bone loss with rapid weight loss. "Ozempic face" is cosmetic concern, not medical. Long-term safety data accumulating.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition